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Glucagon is important for maintaining euglycemia during fasting/
starvation, and abnormal glucagon secretion is associated
with type 1 and type 2 diabetes; however, the mechanisms of
hypoglycemia-induced glucagon secretion are poorly understood.
We previously demonstrated that global deletion of mitochon-
drial uncoupling protein 2 (UCP2
2/2) in mice impaired glucagon
secretion from isolated islets. Therefore, UCP2 may contribute to
the regulation of hypoglycemia-induced glucagon secretion,
which is supported by our current ﬁnding that UCP2 expression
is increased in nutrient-deprived murine and human islets. Further
to this, we created a-cell–speciﬁc UCP2 knockout (UCP2AKO)
mice, which we used to demonstrate that blood glucose recovery
in response to hypoglycemia is impaired owing to attenuated
glucagon secretion. UCP2-deleted a-cells have higher levels of
intracellular reactive oxygen species (ROS) due to enhanced
mitochondrial coupling, which translated into defective stimulus/
secretion coupling. The effects of UCP2 deletion were mimicked
by the UCP2 inhibitor genipin on both murine and human islets
and also by application of exogenous ROS, conﬁrming that changes
in oxidative status and electrical activity directly reduce glucagon
secretion. Therefore, a-cell UCP2 deletion perturbs the fasting/
hypoglycemic glucagon response and shows that UCP2 is neces-
sary for normal a-cell glucose sensing and the maintenance of
euglycemia. Diabetes 62:1623–1633, 2013
E
levated basal glucagon levels and reduced
hypoglycemia-induced glucagon secretion are
underappreciated and poorly understood aspects
of type 1 and type 2 diabetes (1–3). Although
high plasma glucose normally inhibits glucagon secretion,
it remains unclear whether this in vivo response is medi-
ated by glucose sensing, neuronal modulation, paracrine/
endocrine control, or a combination thereof (4–10). Uncou-
pling protein 2 (UCP2), an inner mitochondrial membrane
protein, is expressed in pancreatic a-cells (11), and its ex-
pression can be induced in adipose tissue by a ketogenic
diet (12), suggesting a role in the fasting response. While the
precise physiological function of UCP2 in islet cells is still
debated, it can mildly dissipate the proton motive force
generated during mitochondrial electron transport and
limit ATP synthesis under certain conditions (13–15). Ad-
ditionally, UCP2 can limit mitochondrial reactive oxygen
species (ROS) production, which can alter associated
signaling pathways and/or protect against oxidative stress
(16–18). In b-cells, UCP2 deletion elicits only small
changes in mitochondrial membrane potential (ΔCm)
with limited effect on ATP (18,19) but rather increases
ROS production, which ampliﬁes insulin secretion (18,20).
a-Cells, like b-cells, have glucose-sensing machinery that
center on KATP channel activity, cellular depolarization, and
calcium inﬂux, triggering exocytosis; however, unlike b-cells,
they are electrically active and secretory at low glucose
concentrations (5,21–24). UCP2 in a-cells could therefore be
an important regulator of glucagon secretion via regulation
of ATP production, plasma membrane potential, and ROS
levels.
Previously, we showed that islets from mice globally
lacking UCP2 (UCP2
2/2) displayed higher basal glucagon
secretion and impaired low glucose–mediated glucagon
secretion (11). Due to UCP2’s wide expression proﬁle in
glucose-sensitive tissues, these changes in a-cell function
in UCP2
2/2 mice could be the result of b-cell and/or extra-
pancreatic deletion. To decipher the role of UCP2 in a-cells
and in the response to fasting, we created an a-cell–speciﬁc
UCP2 knockout (UCP2AKO) deletion mouse model. These
mice displayed reduced fasting plasma glucagon levels and
impaired glucagon secretion, due in part to elevated ROS,
enhanced glucose-induced hyperpolarization of the ΔCm,
and depolarization of plasma membrane potential. There-
fore, we conclude that a-cell UCP2 plays a key role in the
hypoglycemic response.
RESEARCH DESIGN AND METHODS
Animals. LoxUCP2 mice on a 129/SV background (25) (Fig. 1A) were crossed
for at least four generations to rat glucagon promoter-driven Cre recombinase
(Gcg-cre) mice maintained on a C57BL/6 background (26). Male mice were geno-
typed using standard PCR (Supplementary Fig. 1A and Supplementary Table 1) and
used for experiments at age 6–8 weeks. Gcg-cre mice were used as experimental
controls, as Gcg-cre and ﬂoxed mice had similar phenotypes (Supplementary
Fig. 2). For imaging experiments, loxUCP2 mice were crossed to Gcg-cre-
ROSA26EYFP mice (27) for at least four generations, producing mice with both
a-cell–speciﬁc UCP2 deletion and expression of eYFP (UCP2AKO-YFP). All
experiments were approved by the Animal Care Committee (University of
Toronto) and animals handled according to the Canadian Council of Animal
Care guidelines.
Human islets. Human islets from review board approved healthy donors were
isolated using the Edmonton protocol (28,29) and provided by the Clinical Islet
Laboratory or IsletCore (University of Alberta, Edmonton, Canada). Islets
were picked into RPMI media with 10% FBS and cultured overnight before
experimentation.
Antibodies and reagents. The monoclonal Cre antibody was from Covance
(San Diego, CA) and the polyclonal UCP2 antibody from Everest Biotech
(Oxfordshire, U.K.). Guinea pig anti-swine insulin (Dako Canada), rabbit anti-
human glucagon (Dako Canada), and ﬂuorescein isothiocyanate– and cyanine
5–labeled secondary antibodies (Jackson ImmunoResearch) were also used.
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ORIGINAL ARTICLERhodamine 123, H2O2, and RedTaq polymerase were from Sigma-Aldrich.
Genipin was from Wako.
Immunoﬂuorescent staining. Dispersed islet cells plated onto glass cover-
slips were ﬁxed, stained with antibodies, and ﬂuorescence visualized using
a laser-scanning confocal microscope (Zeiss 510 LSM) (11).
Plasma hormone concentration and tolerance tests
Insulin tolerance tests. After a 4-h fast, insulin (1.75 IU/kg body wt) was
injected intraperitoneally and blood glucose levels were measured at 0, 15, 30,
60, and 120 min. Plasma glucagon was measured at 0 and 30 min by RIA
(Millipore).
Oral glucose tolerance test. After a 4-h fast, glucose (3 g/kg body wt) was
gavaged and blood glucose levels were measured at 0, 5, 10, 15, 30, 60, and 120
min. Plasma active glucagon-like peptide (GLP)-1 (Meso Scale Discovery,
Gaithersburg, MD) was measured at 0 and 10 min.
Fasting/re-feeding hepatic gluconeogenenic gene expression, hepatic
glycogen, and plasma metabolites. Plasma glucose, glucagon, insulin, and
corticosterone (MP Biomedicals, Irvine, CA) were measured in fed, 24-h fasted,
and 12-h re-fed mice. Mice were killed under fasting or re-fed conditions, and
liver RNA was extracted using Trizol (Invitrogen, Canada) for measurement of
gluconeogenic and glycolytic enzyme genes (Supplementary Table 1). The
glycogen content of livers from 24-h fasted and 12-h re-fed mice was extracted
as previously described (30) and measured using a colorimetric kit (Bio-
vision). The relative concentrations of plasma metabolites were measured
in 100 mL plasma from fed and 24-h fasted mice by mass spectrometry
(Metabolon). Sample preparation, metabolite identiﬁcation, data normali-
zation, and statistical analysis were performed as previously described (31).
Islet glucose-inhibited glucagon secretion. Fresh isolated islets (mouse
or human) were handpicked into 11 mmol/L glucose RPMI media with 10%
FBS and preincubated for 1 h with or without genipin (50 mmol/L) or H2O2 (16
mmol/L), which remained throughout the protocol. Fifteen islets per condition
were preincubated for 15 min with 20 mmol/L glucose Krebs-Ringer buffer
(KRB) (11) before incubation with either high- (20 mmol/L) or low- (1 mmol/L)
glucose KRB for 1 h. Glucagon concentrations were determined by RIA
(Millipore) and normalized to DNA content.
Mitochondrial membrane potential (ΔCm). a-Cells were identiﬁed by YFP
ﬂuorescence before rhodamine 123 (25 mg/mL; 10 min) loading in 1 mmol/L
glucose KRB on the microscope stage. The cells were then washed and imaged
in 1 and 20 mmol/L glucose KRB. NaN3 (5 mmol/L) was added to fully de-
polarize the ΔCm (11).
Islet ATP content and intracellular calcium. Islet ATP content was mea-
sured as previously described using 15 islets per condition (18). Cells were
preincubated with or without H2O2 (16 mmol/L) or genipin (50 mmol/L) for 1 h
in 11 mmol/L glucose RPMI and then loaded with 2 mmol/L Fura-2 AM
(Molecular Probes; Invitrogen) in 20 mmol/L glucose KRB for 45 min before
imaging of cytosolic calcium in YFP
+ a-cells (32).
Electrophysiology. Electrophysiological recordings of KATP currents in YFP
+
a-cells were performed as previously described (33). Plasma membrane po-
tential was measured using a perforated patch technique in whole-cell con-
ﬁguration. The extracellular solution for membrane potential measurements
contained (in millimoles per liter) 140 NaCl, 3.6 KCl, 0.5 MgSO4, 1.5 CaCl2,1 0
HEPES, 0.5 NaH2PO4, 5 NaHCO3 (pH 7.4 with NaOH), and 20 glucose. The
intracellular solution contained (in millimoles per liter unless otherwise in-
dicated) 76 K2SO4, 10 KCl, 10 NaCl, 1 MgCl2, 5 HEPES (pH 7.35 with KOH),
and 60 mg/mL gramicidin (34). Cells displaying input resistance ,25 MV were
studied. Average membrane potentials were calculated across 40 s of steady-
state recordings.
ROS accumulation in isolated islets and its effect on glucagon
secretion. The levels of superoxide and H2O2 were determined using
MitosoxRed and 29,79-dichlorodihydro ﬂuorescein diacetate (CM-H2-DCFDA),
respectively (Molecular Probes; Invitrogen) (35). Fresh isolated islets were
preincubated with or without H2O2 (16 mmol/L) or genipin (50 mmol/L) in 11
mmol/L glucose RPMI for 1 h, followed by 1 mmol/L glucose KRB with or
without treatments for 1 h before measurement of superoxide or H2O2 levels.
Alternatively, islets were cultured overnight in 11 mmol/L glucose RPMI and then
H2O2 levels measured with CM-H2-DCFDA.
Quantitative real-time PCR. Quantitative PCR was performed as previously
described (18,32). Primers are listed in Supplementary Table 1.
Statistics. Statistical signiﬁcance was assessed using either the Student t test
or a two-way ANOVA for repeated measures followed by a Bonferroni posttest
comparison using GraphPad Prism 4. P , 0.05 was considered signiﬁcant. All
data are means 6 SEM.
RESULTS
Deletion of a-cell UCP2 impairs glucagon secretion in
response to hypoglycemia. Truncated UCP2, indicative
of exon 3 and 4 deletion, was observed only in islets and
not in the intestine or hypothalamus of UCP2AKO mice
FIG. 1. UCP2 is efﬁciently deleted speciﬁcally from islet a-cells of UCP2AKO mice. A: Schematic diagram of the UCP2-targeting construct. B:C r e
and UCP2 tissue expression measured by standard PCR. C: Immunostaining for UCP2 protein (red) and glucagon (green) in dispersed islet cells
from Gcg-cre and UCP2AKO mice. UCP2AKO islet cells were also stained for Cre (red) and glucagon (green) or insulin (green). Colocalization is
indicated by yellow and arrows. N =3 .
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in 72 6 10% glucagon-positive cells (Supplementary Fig. 1B)
suggesting efﬁcient deletion. Immunoﬂuorescent staining
of dispersed UCP2AKO islets showed cre protein only in
a-cells (Fig. 1C), and speciﬁc deletion of UCP2 from
UCP2AKO a-cells was conﬁrmed by the absence of UCP2
only in glucagon-positive cells (Fig. 1C). Cre (YFP stain-
ing) was not expressed in the nucleus of the solitary tract
or the distal ileum, reinforcing the speciﬁcity of the glu-
cagon promoter for a-cells (Supplementary Fig. 3).
UCP2AKO and Gcg-cre mice displayed similar insulin
sensitivities, as the rate and magnitude of blood glucose re-
duction during an insulin tolerance test were equal (Fig. 2A);
however, the rate of blood glucose recovery was slower in
UCP2AKO mice, resulting in signiﬁcantly lower blood
glucose at 120 min (Fig. 2A). This correlated with lower
glucagon levels 30 min after insulin injection (just before
blood glucose levels increased) (Fig. 2B), suggesting that
UCP2AKO mice have impaired hypoglycemia-induced
glucagon secretion.
Mice lacking glucagon receptors are more glucose toler-
ant compared with wild-type mice (36). Therefore, we
tested whether UCP2AKO mice that display impaired glu-
cagon secretion were more glucose tolerant. An oral glu-
cose tolerance test showed that UCP2AKO mice had similar
glucose tolerance to Gcg-cre mice (Fig. 3A) and secreted
the same amount of active GLP-1 into plasma (Fig. 3B).
a-Cell UCP2 deﬁciency impairs hepatic gluconeogenic
gene expression and causes a switch of fatty acid
usage in response to a prolonged fast. To assess the
effect of impaired glucagon secretion in UCP2AKO mice,
we examined the effect of prolonged fasting/re-feeding on
glucose homeostasis, hepatic gluconeogenesis, and glyco-
genolysis. Although blood glucose (Fig. 4A) and plasma
insulin (Fig. 4C) were similarly decreased upon fasting, the
UCP2AKO mice displayed reduced fasting plasma gluca-
gon (Fig. 4B). The difference in plasma glucagon levels
was not due to impaired secretion of corticosterone, as the
levels were similarly increased upon fasting (Supplemen-
tary Fig. 4A).
The liver is the major target organ for glucagon in vivo,
and so we explored the effect of prolonged fasting/re-
feeding on hepatic glucose metabolism genes and glycogen
content. After fasting, UCP2AKO livers displayed impaired
induction of the gluconeogenic genes phosphoenolpyruvate
carboxykinase (Pepck) (Fig. 4D) and glucose-6-phosphatase
(G6pc)( F i g .4 E). Conversely, the glycolytic gene, glucokinase
(Gck), was signiﬁcantly higher (Fig. 4G). The expression of
fructose 1,6-bisphosphatase (Fbp1) decreased and fatty acid
synthase (Fasn) increased similarly upon re-feeding (Fig.
4F and H), suggesting an intact response for these genes.
The reduced gluconeogenic gene expression in the UCP2AKO
mice supports their impaired glucagon secretion in response
to hypoglycemia. Glycogen levels were 2.5-fold higher in
UCP2AKO livers upon fasting (Fig. 4I), also reﬂecting their
lower glucagon levels.
A targeted mass spectrometry approach examining mul-
tiple metabolic pathways was used to determine the effect
of reduced glucagon secretion and the impaired hepatic
gluconeogenic response to fasting on plasma metabolites.
Of the 307 identiﬁed biochemicals, 157 were signiﬁcantly
changed upon fasting and 63 showed a fed-state, genotype
interaction (P , 0.05). Levels of the ketone body
3-hydroxybutarate normally increase upon fasting, and
the response of this metabolite was intact in UCP2AKO
mice (Supplementary Fig. 4B). Interestingly, several abnor-
malities in lipid metabolism products were observed in
UCP2AKO mice. The levels of medium chain–length fatty
acids (MCFA) were similar in fed plasma; however, their
concentration decreased in UCP2AKO and increased in
Gcg-cre mice upon fasting (Fig. 4J and Supplementary
Fig. 4C), suggesting that UCP2AKO mice may preferentially
use MCFAs as an energy source under these conditions.
UCP2 expression is increased after nutrient depletion
in islets, and a-cell UCP2 deﬁciency/inhibition impairs
glucagon secretion from isolated islets. Human and
mouse islets deprived of nutrients (low serum and low
glucose) showed similar induction of glucagon and UCP2
expression, highlighting the potential importance of UCP2
during fasting (Fig. 5A and B). We therefore assessed the
ability of fresh-isolated UCP2AKO mouse islets to secrete
glucagon under low glucose conditions. When conditions
were switched from high to low glucose, glucagon secretion
was signiﬁcantly stimulated in Gcg-cre and UCP2AKO islets
(P , 0.001) (Fig. 5D); however, the amount secreted by
UCP2AKO islets was 52 and 31% lower under high and low
glucose concentrations, respectively. Total glucagon content
and islet morphology were similar in the two genotypes,
suggesting that the reduced secretion from UCP2AKO islets
was not due to reduced glucagon content or a-cell number
(data not shown).
Gcg-cre islets exposed to genipin, a compound known to
inhibit UCP2 (37), secreted signiﬁcantly less glucagon in
the presence of low glucose, and this level was similar
FIG. 2. a-Cell UCP2 deletion reduces glucagon secretion in vivo.A : Blood glucose during an intraperitoneal insulin tolerance test (ipITT). *P < 0.05.
N =1 2 –15. B: Plasma glucagon levels at 0 and 30 min during the ipITT. N =6 –8m i c e / g r o u p .*P < 0.05; **P < 0.01.
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(Fig. 5E). Conversely, preincubation of UCP2AKO islets
with genipin did not alter glucagon secretion (Fig. 5E). For
assessment of the interspecies effect of UCP2 inhibition on
glucagon secretion, human islets were also exposed to
genipin. They secreted signiﬁcantly less glucagon under
low glucose conditions, which was similar to high glucose
levels alone (Fig. 5C). Therefore, acute inhibition of UCP2
with genipin reduces glucagon secretion under stimulatory
low glucose conditions.
a-Cell UCP2 deﬁciency increases glucose-induced ΔCm
hyperpolarization, which leads to altered oxidative
status and impaired glucagon secretion. To determine
the contribution of UCP2 to mitochondrial coupling in
a-cells, we measured changes in glucose-induced ΔCm
hyperpolarization (Fig. 6A). Basal (1 mmol/L glucose)
ΔCm was similar, but UCP2AKO-YFP a-cells displayed sig-
niﬁcantly greater glucose-induced hyperpolarization of ΔCm
(Fig. 6B).
Even small increases in ΔCm can translate into signiﬁ-
cantly large increases in mitochondrial ROS production,
and recently ROS signaling has emerged as an important
regulator of insulin secretion (18,20,38). In contrast, chronic
oxidative stress can impair secretion (17,35). As such, we
compared the levels of intracellular ROS (H2O2 and mito-
chondrial superoxide) in fresh-isolated islets (to correlate
with glucagon secretion studies [Fig. 5D]) and H2O2 in
cultured islets. No difference in the amount of H2O2 but
signiﬁcantly more mitochondrial superoxide was observed
in fresh-isolated UCP2AKO islets (Fig. 6C and D). Appli-
cation of genipin increased H2O2 levels 1.37-fold in Gcg-cre
islets only (P , 0.01) and increased both H2O2 and su-
peroxide levels in human islets (Fig. 6H and I). Therefore,
UCP2 deﬁciency in mouse a-cells results in superoxide
buildup and an inability to convert superoxide to H2O2.
However, after overnight culture, UCP2AKO islets dis-
played ~1.7-fold greater intracellular H2O2 (Fig. 6E). Cul-
tured Gcg-cre islets appeared to recover from the stress of
isolation, as H2O2 levels were lower than in fresh-isolated
islets (Fig. 6C), suggesting that ROS production is increased
in UCP2AKO islets and they experience a chronically al-
tered oxidative status. Whole-islet data were conﬁrmed in
dispersed, cultured a-cells, as overall ROS levels were
higher in UCP2AKO a-cells (Supplementary Fig. 5). In
addition, treatment of Gcg-cre a-cells with genipin in-
creased ROS to a similar level as UCP2AKO a-cells,
whereas genipin had no further effect on UCP2AKO a-cells
(Supplementary Fig. 5).
Intracellular ROS levels were correlated with expres-
sion of several antioxidant-related genes in fresh isolated
whole islets. The expression of superoxide dismutase
2( Sod2) was 88% lower in UCP2AKO islets (Fig. 6F), con-
sistent with their inability to convert superoxide to H2O2,
whereas the H2O2-scavenging glutathione peroxidase
(Gpx) and catalase (Cat) and the cytoprotective gene,
Heme Oxygenase 1 (Ho-1), were unchanged (Supplemen-
tary Fig. 6A).
To determine whether increased ROS contribute to im-
paired glucagon secretion from UCP2AKO islets, we in-
creased intracellular ROS with exogenous H2O2 application
(Fig. 6C and D). Gcg-cre islets preincubated with H2O2 se-
creted signiﬁcantly more glucagon under high-glucose and
less under low glucose conditions (Fig. 6G). The increased
glucagon secretion in the presence of high glucose plus
H2O2 occurred despite signiﬁcantly greater insulin secretion
(Supplementary Fig. 6C). The addition of H2O2 to UCP2AKO
islets did not alter glucagon secretion (Fig. 6G). Similarly,
the addition of H2O2 had no effect on glucose-mediated
insulin secretion from UCP2AKO islets (Supplementary
Fig. 6C). Therefore, elevated ROS levels in control islets
impaired glucagon secretion similarly to UCP2AKO islets,
which experience endogenously higher ROS levels and
altered oxidative status.
Impaired glucagon secretion from UCP2-deﬁcient
a-cells correlates with enhanced depolarization of
plasma membrane potential and reduced calcium.
Metabolism of glucose and further closure of KATP chan-
nels reduce glucagon secretion (24). Therefore, we mea-
sured KATP current and plasma membrane potential. KATP
currents in Gcg-cre-YFP and UCP2AKO-YFP a-cells could
be similarly activated and inhibited by diazoxide and tol-
butamide, respectively (Supplementary Fig. 7A). However,
despite a similar magnitude of change in plasma mem-
brane potential when switched from high to low glucose,
the plasma membrane was more depolarized in UCP2AKO-
YFP a-cells under both conditions (Fig. 7A and B). Pre-
incubation of Gcg-cre-YFP a-cells with high glucose plus
genipin increased (depolarized) plasma membrane potential
FIG. 3. UCP2AKO mice display normal glucose tolerance and GLP-1 secretion. A and B: Oral glucose tolerance test; mice were gavaged with 3 g/kg
glucose after a 4-h fast (N =7 –8 mice/genotype). Blood glucose (A) and plasma active GLP-1 (B) were measured. The inset panel in A shows the
incremental area under the glucose curve (iAUC).
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Therefore, the absence of UCP2 in a-cells shifts the op-
erating range of plasma membrane potentials, which might
explain the impaired glucagon secretion.
The more depolarized plasma membrane potential in
the presence of high glucose suggests that a-cell UCP2
deﬁciency may increase ATP levels and close/inactivate
KATP channels. There was a trend toward increased ATP
content in UCP2AKO islets under high glucose conditions
(Supplementary Fig. 7B); however, any effect of a-cell
UCP2 deletion may be masked by b-cell ATP content.
Therefore, we determined whether the KATP channel
FIG. 4. a-Cell UCP2 deletion reduces the gluconeogenic response of the liver and switches fatty acid usage during a prolonged fast. Blood glucose
(A), plasma glucagon (B), and plasma insulin (C) measured in fed, 24-h fasted (fasting), and 12-h re-fed mice. *P < 0.05. D–H: Hepatic expression
of the enzymes Pepck (D), G6pc (E), Fbp1 (F), Gck (G), and Fasn (H) genes. N =4 –8/group. *P < 0.05 or **P < 0.01 compared with Gcg-cre.
I: Hepatic glycogen levels. N =4 –6 mice/condition. *P < 0.05. J: Metabolomic analyses of MCFA and long-chain fatty acid (LCFA) plasma levels.
Data are relative to Gcg-cre levels. N = 8 mice/genotype. *P < 0.05 genotype/fed-state interaction.
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Under high glucose conditions, the addition of low-dose
diazoxide (1 mmol/L) increased glucagon secretion from
UCP2AKO islets to a level similar to that in Gcg-cre islets
without diazoxide; however, the UCP2AKO islets were
unable to reach a level of secretion as high as that in
Gcg-cre islets in the presence of 1 mmol/L diazoxide (Fig. 7D).
Conversely, under low glucose conditions, low-dose diazo-
xide increased glucagon secretion from UCP2AKO islets to
a level similar to that in Gcg-cre islets in the absence of
diazoxide. The addition of more diazoxide dose-dependently
decreased secretion (Fig. 7D), which was similar to previous
observations (24). Therefore, under low glucose conditions
opening KATP channels can correct the glucagon secretion
defect observed in UCP2AKO islets.
Inﬂux of calcium is required for low glucose–mediated
exocytosis of glucagon (39), and thus we examined
changes in cytosolic calcium. The amount of intracellular
calcium under high and low glucose conditions was re-
duced in YFP-UCP2AKO a-cells (Fig. 7F). Pretreatment of
YFP-Gcg-cre cells with genipin also signiﬁcantly reduced
intracellular calcium levels, whereas H2O2 had no effect
(Fig. 7F). In addition, intracellular calcium in UCP2AKO
a-cells oscillated faster under low glucose conditions (Sup-
plementary Fig. 8E). Reduced cytosolic calcium in UCP2AKO
a-cells reﬂects an impaired ability to secrete glucagon.
FIG. 5. UCP2 expression is increased after nutrient depletion and glucagon secretion from UCP2AKO islets was impaired. Human (left panel) and
mouse (right panel). A: UCP2 (i) and GCG (ii) expression in human islets exposed to low serum (0.01% FBS) and low glucose (2.8 mmol/L) RPMI
(low serum and low glucose [LSLG]) for 6 h. N = 6 individual donors. B: Ucp2 (i) and Gcg (ii) expression in control CD1 mouse islets exposed to
LSLG for 6 h. N =4 –5/condition. C: Glucose-inhibited glucagon secretion from human islets preincubated with or without genipin (50 mmol/L)
during a half-hour static incubation. N =6 –7 donors. D: Glucose-inhibited glucagon secretion was measured from fresh-isolated islets incubated
with high glucose (HG) (20 mmol/L), low glucose (LG) (1 mmol/L), or low glucose plus arginine (LG 1 Arg) (10 mmol/L). N =8 –9 mice/genotype.
E: Glucose-inhibited glucagon secretion measured from islets preincubated with or without genipin (50 mmol/L). N =7 –9 mice/genotype. All mouse
data are normalized to DNA, but the human data are per islet. *P < 0.05.
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relative ﬂuorescent unit (RFU) measurements in YFP
+ a-cells. B: ΔCm (Mmp) was measured in high glucose (20 mmol/L) (Δ1) and NaN3 (5 mmol/L)
(Δ2) and normalized to basal ﬂuorescence in the presence of low glucose (1 mmol/L). N =2 8 –29 cells from 6 mice/genotype. *P < 0.05. C and D:
Fresh-isolated islets were cultured with or without H2O2 (16 mmol/L) or genipin (50 mmol/L) before measurement of H2O2 (CM-H2-DCFDA) (C)o r
superoxide (MitosoxRed) (D). N =2 0 –28 islets, 6–8 mice/genotype. *P < 0.05, **P < 0.01. E: Islets were cultured overnight, and then intracellular
H2O2 (CM-H2-DCFDA) was measured. N =1 9 –27 islets, 5–7 mice/genotype. *P < 0.05. F: Islet Sod2 expression. N =4 –5 mice/genotype. *P < 0.05. G:
Glucose-inhibited glucagon secretion with or without H2O2 (16 mmol/L). Secretion is per microgram of DNA, normalized to Gcg-cre high glucose
(HG) conditions. LG, low glucose. N =3 –11 mice/genotype. *P < 0.05, **P < 0.01. H and I: Human islets were incubated with 50 mmol/L genipin for 2
h before measurement of H2O2 (CM-H2-DCFDA) (H) and superoxide (MitosoxRed) (I) levels. N = 4 individual donors. *P < 0.05, **P < 0.01.
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a-Cells secrete glucagon in response to low blood glucose
and are inhibited when blood glucose levels rise (24). We
now show that UCP2 expression is increased in islets de-
prived of nutrients, a-cell UCP2 is necessary for appro-
priate glucagon secretion, and the absence of UCP2
impairs a-cell function. UCP2AKO mice displayed im-
paired glucagon secretion in vivo, which inhibited the he-
patic response to hypoglycemia (40), including reduced
expression of the hepatic gluconeogenic genes, Pepck and
G6pc, and higher glycogen levels. Reduced fasting levels of
plasma MCFAs in UCP2AKO mice suggest compensation
for impaired hepatic gluconeogenesis and increased usage
of these fatty acids during hypoglycemia. MCFAs are
absorbed directly through the portal vein, making them
a direct energy source for the liver (41). MCFAs also
produce more ketones per unit of energy than long-chain
fatty acids, which could provide crucial energy for the
brain during nutrient depletion and when gluconeogenesis
is impaired, such as in fasted UCP2AKO mice. Similarly,
mice globally lacking glucagon receptors demonstrate
impaired activation of hepatic gluconeogenic genes and
FIG. 7. UCP2AKO a-cells have more depolarized plasma membranes and reduced intracellular calcium. A: Representative traces of plasma
membrane potential in YFP
+ a-cells incubated in high (20 mmol/L) and low (1 mmol/L) glucose. B: Average membrane potential in YFP
+ a-cells. N =
5–8 cells, 3 mice/genotype. *P < 0.05. C: Average plasma membrane potential measured in YFP
+ a-cells (N =8 –13) with or without genipin (50
mmol/L) (N = 5 cells), and at least 3 mice/genotype. *P < 0.05, **P < 0.01. D: Glucose-inhibited glucagon secretion from islets incubated with or
without diazoxide (1, 10, and 100 mmol/L) in the presence of high glucose (20 mmol/L) (i) or low glucose (1 mmol/L) (ii). *P < 0.05. N = 3 mice/
genotype. E: Representative traces of cytosolic calcium uptake in YFP
+ a-cells switched from high glucose (HG) (20 mmol/L) to low glucose (LG)
(1 mmol/L) and then in the presence of arginine (Arg) (10 mmol/L), KCl (30 mmol/L), and the L-type calcium blocker nifedipine (Nif) (10 mmol/L).
F: Incremental area under the curve (iAUC) for cytosolic calcium, normalized to high glucose plus arginine levels. Representative traces are shown
in Supplementary Fig. 8. *P < 0.05. N =1 9 –40 cells/treatment, 3 mice/genotype.
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(36,42). Interestingly, UCP2AKO mice, similar to adult mice
with 98% a-cell ablation (43), displayed normal glucose
tolerance. Therefore, we show that appropriate glucagon
secretion is required for normal hepatic function during
fasting and that a-cell UCP2 deﬁciency disrupts this pro-
cess, solidifying the role of UCP2 in the a-cell response to
hypoglycemia.
The amount of glucagon secreted from UCP2AKO islets
under stimulatory conditions was the same as that se-
creted from Gcg-cre islets under inhibitory conditions.
Preincubation of Gcg-cre islets with the UCP2 inhibitor
genipin reduced low glucose–mediated glucagon secretion
by a magnitude similar to that in UCP2 deletion, whereas
genipin did not further reduce glucagon secretion from
UCP2AKO islets, suggesting its relative speciﬁcity of ac-
tion for UCP2. Interestingly, the glucagon-lowering effect
of genipin was not isolated to mouse islets, as it also sig-
niﬁcantly impaired low glucose–mediated glucagon se-
cretion from human islets. Insulin released from b-cells
lowers glucagon secretion via paracrine inhibition (5,7,9);
however, the reduced glucagon secretion from UCP2AKO
islets was not explained by this mechanism, as insulin
secretion was similar from Gcg-cre and UCP2AKO cul-
tured islets (Supplementary Fig. 6B). Therefore, the pres-
ence of UCP2 in a-cells is directly required for appropriate
glucagon release.
The a-cell secretes glucagon within a narrow range of
plasma membrane potentials (24) and is sensitive to small
changes in ATP concentration (22), and it is suggested that
glucose metabolism does not accelerate ATP synthesis in
this cell type (44). We previously showed that UCP2 is
expressed at higher levels in a compared with clonal b-cell
lines (11). Thus, high expression of UCP2 may normally
limit ATP production in a-cells via an uncoupling role.
Furthermore, small interfering RNA knockdown of UCP2
in clonal a-cells increased ATP levels (11). Although no
difference in ATP concentrations in UCP2AKO versus
Gcg-cre islets was detected, the increased glucose-induced
hyperpolarization of ΔCm and more depolarized plasma
membrane of UCP2AKO a-cells suggest increased ATP
synthesis. Recent studies show that depolarization of a-cells
inhibits the activity of Na
+ and Ca
2+ channels resulting in
cessation of glucagon secretion (22,24), and we show
reduced intracellular calcium levels in UCP2AKO a-cells
under both high and low glucose conditions. Similarly, ex-
posure of Gcg-cre a-cells to genipin depolarized the plasma
membrane and reduced calcium entry. As such, we propose
that UCP2AKO a-cells have more closed KATP channels,
limiting their glucagon secretion capacity (24,45). It was no
surprise that the addition of low-dose diazoxide, which
opens the KATP channel, corrected this impairment under
low glucose conditions. Conversely, in the presence of high
glucose, low-dose diazoxide increased glucagon secretion
from UCP2AKO islets to a level similar to basal secretion
from Gcg-cre islets, yet further addition of diazoxide did not
elevate secretion from UCP2AKO islets. These data suggest
that altered membrane potential is not the only factor lim-
iting glucagon secretion from UCP2AKO islets under high
glucose conditions.
It has been proposed that generation of low-level ROS,
likely H2O2,a m p l i ﬁes insulin secretion (20,46), and recently,
FIG. 8. UCP2 is required for normal glucagon secretion in response to hypoglycemia. A: UCP2AKO islets displayed increased glucose-induced
hyperpolarization of ΔCm, which caused increased ROS and perhaps ATP production. The altered coupling and ROS status resulted in greater
depolarization of the plasma membrane, and although still responsive to changes in glucose, the UCP2AKO a-cells showed reduced calcium entry
and lower glucagon secretion. B: UCP2 expression is normally increased in islets deprived of nutrients. Therefore, lack of UCP2 in a-cells results in
impaired glucagon secretion during hypoglycemia. ITT, insulin tolerance test; TCA, tricarboxylic acid.
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insulin secretion in an ROS-dependent manner (18). We
now show that the acute addition of exogenous H2O2 to
control islets increased glucagon secretion under high
glucose and reduced glucagon secretion under low glu-
cose conditions, a situation reminiscent of the disordered
glucagon secretion from murine UCP2
2/2 islets (11) and
patients with diabetes (1) and human islets exposed to
genipin. It is therefore conceivable that UCP2 regulates the
levels of ROS in a-cells and, in turn, glucagon secretion.
Acute inhibition of UCP2 in Gcg-cre islets with genipin
increased endogenous H2O2 levels, which correlated with
reduced low glucose–mediated glucagon secretion. Simi-
larly, UCP2AKO islets had elevated mitochondrial super-
oxide levels and signs of chronically altered redox-related
signaling pathways (i.e., ROS levels remained high after
overnight culture and altered antioxidant gene expression
[including reduced Sod2 expression] was observed), which
also correlated with impaired glucagon secretion. There-
fore, elevated intracellular ROS can reduce low glucose–
mediated glucagon secretion, although the speciﬁc ROS
species and its signaling targets are unclear.
We propose that a-cell UCP2 expression is normally
increased in response to low nutrient levels and limits
ΔCm hyperpolarization, which, by limiting ATP and/or ROS
production, contributes to the cells’ ability to secrete glu-
cagon. Therefore, a-cell–speciﬁc deletion of UCP2 results
in greater depolarization of the plasma membrane and,
although still responsive to changes in glucose, reduces
calcium entry and lowers overall secretion capacity (Fig.
8A). Deletion of a-cell UCP2 disrupted the hypoglycemic
response in mice, implying that increased UCP2 expres-
sion/activity, such as that which occurs after fasting, is
required to promote glucagon secretion and is protective
in this role (Fig. 8B). Conversely, elevated expression or
activity of UCP2 may also contribute to the dysregulated
glucagon secretion that is observed in the diabetic state.
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